Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease by Hyslop LA et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Hyslop LA, Blakeley P, Craven L, Richardson J, Fogarty NME, Fragouli E, Lamb 
M, Wamaitha SE, Prathalingam N, Zhang Q, O’Keefe H, Takeda Y, Arizzi L, 
Alfarawati S, Tuppen H, Irving L, Kalleas D, Choudhary M, Wells D, Murdoch 
AP, Turnbull DM, Niakan KK, Herbert M. Towards clinical application of 
pronuclear transfer to prevent mitochondrial DNA 
disease. Nature 2016, 534(7607), 383-386. 
 
Copyright: 
This is the authors’ accepted manuscript of an article published in its final definitive form by Springer 
Nature, 2016. 
For the terms of reuse please see http://www.nature.com/authors/policies/license.html  
DOI link to article: 
http://dx.doi.org/10.1038/nature18303  
Date deposited:   
28/07/2016 
Embargo release date: 
08 December 2016  
1Towards clinical application of pronuclear transfer to prevent mitochondrial DNA 
disease
Louise A. Hyslop1, 2
Paul Blakeley3
Lyndsey Craven4
Jessica Richardson1
Norah M.E. Fogarty3
Elpida Fragouli5
Mahdi Lamb1
Sissy E. Wamaitha3
Nilendran Prathalingam1, 2
Qi Zhang1
Hannah O’Keefe1
Yuko Takeda1
Lucia Arizzi 1, 2
Samer Alfarawati5
Helen A. Tuppen4
Laura Irving1
Dimitrios Kalleas1
Meenakshi Choudhary2
Dagan Wells6
2Alison P Murdoch2
Douglass M. Turnbull4
Kathy K. Niakan3
Mary Herbert1, 2
1 Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, 
Biomedicine West Wing, Centre for Life, Times Square, Newcastle upon Tyne, NE1 
3BZ, UK
2 Newcastle Fertility Centre, Biomedicine West Wing, Centre for Life, Times Square, 
Newcastle upon Tyne, NE1 4EP, UK 
3 The Francis Crick Institute, Human Embryo and Stem Cell Laboratory, Mill Hill
Laboratory Mill Hill, London, NW7 1AA, UK
4 Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, 
Newcastle University, The Medical School, Framlington Place, Newcastle upon Tyne, 
NE2 4HH, UK
5 Reprogenetics UK, Institute of Reproductive Sciences, Oxford Business Park North, 
Oxford OX4 2HW, UK
6 University of Oxford, Nuffield Department of Obstetrics and Gynaecology, John 
Radcliffe Hospital, Oxford OX3 9DU, UK
Mitochondrial DNA (mtDNA) mutations are maternally inherited and are associated 
with a broad range of debilitating and fatal diseases1. Reproductive technologies 
3designed to uncouple the inheritance of mtDNA from nuclear DNA may enable 
affected women to have a genetically related child with a greatly reduced risk of 
mtDNA disease. Here we report the first preclinical studies on pronuclear 
transplantation (PNT). Surprisingly, techniques used in proof of concept studies 
involving abnormally fertilized human zygotes2 were not well tolerated by normally 
fertilized zygotes. We have therefore developed an alternative approach based on 
transplanting pronuclei shortly after completion of meiosis rather than shortly before 
the first mitotic division. This promotes efficient development to the blastocyst stage 
with no detectable effect on aneuploidy or gene expression. Following optimisation, 
mtDNA carryover was reduced to <2% in the majority (79%) of PNT blastocysts. The 
importance of reducing carryover to the lowest possible levels is highlighted by a
progressive increase in heteroplasmy in a stem cell line derived from a PNT blastocyst 
with 4% mtDNA carryover. We conclude that PNT has the potential to reduce the risk 
of mtDNA disease, but it may not guarantee prevention.
Predicting the risk of serious disease in children of women who carry mtDNA 
mutations is complicated by a number of factors. Mutations in mtDNA can be either 
homoplasmic (all copies of mtDNA are mutated) or heteroplasmic (mixture of mutated 
and wild-type mtDNA). In the case of heteroplasmy, women produce oocytes with 
widely varying mutation loads3. While pathogenicity is generally proportional to the 
ratio of mutated to wild-type mtDNA, the severity of disease for a given mutation load 
can vary, even amongst homoplasmic individuals4. The resulting unpredictability in the 
risk of transmitting disease raises profoundly difficult reproductive decisions for 
4women from affected families. While preimplantation genetic diagnosis (PGD) can be 
used to reduce the risk of mtDNA disease by identifying embryos with low mutation 
loads5, it is not useful for women who are homoplasmic for pathogenic mtDNA 
mutations6. In such cases, it may be possible to reduce the risk of transmission by 
transplanting the oocyte nuclear DNA to an enucleated donor oocyte free of 
pathogenic mtDNA mutations.  
Progression through female meiosis offers a number of opportunities for transplanting 
nuclear DNA. Proof of concept studies in human7,8, indicate that transplantation of the 
nuclear genome between oocytes arrested at metaphase of meiosis II (MII) is 
associated with a high incidence of abnormal fertilization7. An alternative approach is 
to transplant the nuclear genome after fertilization, when the haploid maternal and 
paternal genomes are separately packaged in large clearly visible pronuclei. First 
performed in mouse zygotes more than three decades ago9, pronuclear transfer (PNT) 
is typically performed during the G2 phase of the 1st mitotic cell cycle. Using this 
approach, we have previously demonstrated that PNT between abnormally fertilized 
human zygotes is technically feasible2. However, their limited capacity for onward 
development has been a major barrier to further investigation of the therapeutic 
potential of PNT. 
Here we investigate the effect of PNT on normally fertilized human zygotes. We found 
that the procedures (Extended Data Fig. 1 a,b) previously used for abnormally 
fertilized zygotes2 resulted in reduced survival. Because developmental competence is 
5correlated with accelerated division to the 2-cell stage10, we asked whether the timing 
of PNT might be too close to onset of 1st mitosis in normally fertilized zygotes (Fig. 
1a). To address this, we undertook a series of experiments in which the PN were 
transplanted shortly after they first appear (~8 hr after insemination; Fig. 1b, Videos 1 
and 2). Initially, we added sucrose to the enucleation medium to facilitate enucleation 
and fusion by inducing shrinkage of the cytoplasm (Fig. 1b). However, this was later 
abandoned to reduce the karyoplast mtDNA content and had minimal effect on 
survival (see below). Our data indicate that early PNT (ePNT) promotes survival (92% 
vs 59% for late PNT (LtPNT); P<0.01; Fig. 1c). Moreover, ePNT zygotes showed 
normal PN abuttal and division to the 2-cell stage (Extended Data Fig. 1 c,d),
indicating that sperm centriole function was not disrupted11. 
Blastocyst formation, which is essential for implantation, is marked by allocation of 
cells to the inner cell mass (ICM), or to an outer layer of trophectoderm (TE) cells12 at 
5-6 days after fertilisation in vitro. The morphology of the ICM and TE correlates well 
with implantation and is used to assess blastocyst quality in clinical IVF programmes
(Extended Data Fig. 2a-d). While the increased survival of ePNT zygotes (Series I) 
resulted in improved blastocyst formation compared with LtPNT, both approaches 
produced few good quality blastocysts (Extended Data Fig. 2e,f). Control experiments 
in which PN were replaced in the same zygote (autologous ePNT) indicated that 
blastocyst quality was compromised by the manipulations (Fig. 2a and Extended Data 
Fig. 2f). To address this we modified the manipulation medium, removing Ca2+ and 
Mg2+ and reducing the HVJ-E concentration tenfold8. In addition, we switched from a 
6two-step to a single-step culture medium, in which embryos remained for the duration 
of culture. Under these conditions (ePNT Series II), blastocyst formation and quality 
did not differ between unmanipulated controls and technical controls (Fig. 2a,b). 
Similarly, heterologous ePNT, which involved reciprocal transfers between zygotes 
from fresh and vitrified oocytes, had no detectable effect on blastocyst quality (Fig.
2b,c). Consistent with the improved quality, nuclear counts indicated that ePNT 
blastocyst cell numbers were equivalent to controls (Extended Data Fig. 2g,h). 
However, heterologous PNT resulted in reduced blastocyst formation (Fig. 2b), 
possibly due to an effect of vitrification at the MII stage13, which was not ameliorated 
by delaying vitrification until after exit from MII (Extended Data Fig. 3a-f).
Analysis of aneuploidy by array-based comparative genomic hybridization (array-
CGH) indicated that while the majority of poor quality ePNT blastocysts were 
aneuploid for multiple chromosomes (Fig. 2d and Extended Data Fig. 4), the overall 
incidence of aneuploidy was comparable between ePNT and control blastocysts, and 
was similar to a reference dataset of IVF blastocysts, in which female age was matched 
to the karyoplast donors (Fig. 2e). These data indicate that the ePNT procedure does 
not result in an increased incidence of aneuploid blastocysts.
We next determined whether ePNT alters the pattern of gene expression in human 
blastocysts by performing RNA sequencing (RNA-seq) on single cells microdissected 
from ePNT and control blastocysts (Extended Data Fig. 5a, b). For reference, we also 
included a previously published series of unmanipulated blastocysts14. The ePNT 
7blastocysts included in these experiments were generated by fusion of cytoplasts and 
karyoplasts with the same (autologous and homologous ePNT), or different 
(heterologous ePNT) mitochondrial genotypes (Extended Data Fig. 5b).  
To test for differences in global gene expression, we performed principal component 
analysis (PCA) on normalized RNA-seq data (Extended Data Fig. 5c). We first 
determined whether PCA is sufficiently sensitive to detect differences in global gene 
expression between good and poor quality blastocysts. Plotting PC1 against PC2, 
which together account for the largest contributions to variation in global gene 
expression, revealed a high proportion of outliers among samples from poor quality
blastocysts (Fig. 3a,b). By contrast, samples from good quality ePNT blastocysts 
clustered closely with controls (Fig. 3c). To determine whether additional principal 
components, however minor, might distinguish differences between good quality ePNT
and control blastocysts, we plotted all combinations of the first 10 principal 
components. In each combination we found that ePNT samples cluster with controls 
(Extended Data Fig. 6a). Furthermore, we were able to distinguish distinct populations 
of cells corresponding to the three cell lineages of the mammalian blastocyst14
(Extended Data Fig. 6b). This was confirmed by t-SNE, a non-linear method for 
dimensionality reduction15 (Extended Data Fig. 6c). Consistent with this, unsupervised 
hierarchical clustering revealed that ePNT and control samples cluster together based 
on lineage (Extended Data Fig. 7a). Together these findings indicate that single cell 
RNA-seq reliably detects differences in gene expression, and that global and lineage-
associated gene expression is indistinguishable between control and ePNT blastocysts.
8To address the question of whether ePNT specifically affects expression of mtDNA-
encoded OXPHOS genes, we generated a heatmap after unsupervised hierarchical 
clustering. This revealed wide variation in the level of mtDNA OXPHOS gene
expression within and between ePNT and control blastocysts. However, samples from
both groups clustered together irrespective of whether the karyoplast and cytoplast 
contained the same, or different, mitochondrial genomes (Extended Data Fig. 7b). This 
suggests that switching nuclear genomes does not alter mitochondrial gene expression. 
Based on evidence from a range of pathogenic mutations, the probability of developing 
or transmitting disease is low when mutation loads are <18%16 and <5%17  
respectively. Thus, reducing the contribution of karyoplast mtDNA to <5% has the 
potential to prevent transmission to subsequent generations. The level of mtDNA 
carryover during PN transfer was measured by pyrosequencing (Extended Data Fig.  
8a-c) using clumps of cells from day 6 ePNT blastocysts (n=40) generated by 
reciprocal transfer between zygotes from fresh and vitrified oocytes (Fig. 4a).  Despite 
removal of excess cytoplasm before karyoplast fusion (Video 2 and Fig. 1b), we found 
that heteroplasmy was >5% in a high proportion (28%) of samples enucleated in the 
presence of sucrose. This was significantly reduced by omission of sucrose (Fig. 4b 
and Extended Data Fig. 8d), most likely due to an osmotic effect. MtDNA carryover 
was further reduced in blastocysts whose cytoplasts originated from freshly harvested 
rather than vitrified oocytes (Fig. 4c), which may be explained by a high incidence of 
cytoplasmic leakage from the latter. Thus, the efficacy of ePNT in preventing mtDNA 
9disease is likely to be increased by vitrifying patient rather than donor oocytes. Based 
on our findings, this approach results in <2% heteroplasmy in the majority (79%) of 
blastocysts and none with >5% heteroplasmy (Extended Data Fig. 8e,f).  Notably, 
those with >2% heteroplasmy were predicted by technical problems such as leakage 
from the cytoplast or inadequate shearing of cytoplasm from the karyoplast. Such 
factors could be taken into account when selecting embryos for use in clinical 
treatment.
To assess the potential fate of karyoplast mtDNA under conditions where it can 
replicate18 , we derived hESC lines (n=5) from ePNT blastocysts (Extended Data Fig.
9a-f). While all PNT-hESC lines showed low levels of heteroplasmy at passage 1 (P1), 
one line (36PNT-hESC), derived from a blastocyst with 4% mtDNA carryover, 
showed an upward drift with wide variation in heteroplasmy between colonies by P12
(Fig. 4d). This was confirmed by experiments in which individual colonies were 
subcloned and cultured for multiple passages (Extended Data Fig. 10). Interestingly, 
the karyoplast and cytoplast donors for 36PNT belonged to the same mtDNA 
haplogroup (Extended Data Fig. 9f), however, we cannot exclude the possibility that 
sequence variants in the karyoplast donor mtDNA might have conferred a replicative 
advantage19. While the biological basis remains to be established, the relevance of the 
increased heteroplasmy to development in vivo is unclear. For example, recent reports 
indicate that pluripotent cells derived from heteroplasmic fibroblasts exhibit a 
bimodal drift towards homoplasmy, which is not observed in the parental 
lines
20,21
.  Moreover, with the exception of one controversial case22,23, a number of 
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reports24,25, together with our own unpublished data, indicate that levels of 
heteroplasmy in preimplantation embryos mirrors that in babies born following PGD. 
Nonetheless, the finding underscores the importance of reducing mtDNA 
carryover to the lowest possible levels and suggests that guaranteed prevention
of disease will depend on complete elimination of karyoplast mtDNA. 
In conclusion, the work reported here represents a significant advance towards 
understanding the therapeutic potential of PNT in preventing transmission of mtDNA 
disease. Transplanting the PN shortly after completion of meiosis resulted in improved 
survival. Further optimization of enucleation and embryo culture procedures promoted 
development of good quality blastocysts whose gene expression and incidence of 
aneuploidy did not differ from controls. Our findings also indicate that vitrification of 
patient rather than donor oocytes will likely minimize mtDNA carryover. This offers
the added advantage of stockpiling patient oocytes before they become susceptible to 
age-related meiotic aneuploidy26. Given the low levels of mtDNA carryover using 
optimised procedures, we believe that ePNT has the potential to reduce risk of 
mtDNA disease. However, until more is known about the post-implantation fate of 
karyoplast mtDNA, it should be considered in combination with prenatal screening. 
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Figure 1 | Early PNT promotes survival of normally fertilized zygotes 
following PNT.
 a, Progression from MII arrest to completion of the 1st mitosis showing 
timings of early PNT (ePNT) and late PNT (LtPNT) b, Images show the steps 
involved in ePNT (i) Arrowheads indicate the pronuclei (PN) (ii) Enucleation 
pipette inserted through a laser-induced opening in the zona pellucida
(arrow, bottom panel). Lower panel, enucleated zygote (cytoplast). Inset 
shows two karyoplasts, each consisting of a single PN surrounded by a small 
amount of cytoplasm. (iii) Karyoplasts treated with HVJ-E and inserted under 
the zona pellucida. Lower panel, arrow indicates removal of excess 
cytoplasm (see Video 2). c, Survival of reconstituted ePNT and LtPNT 
zygotes (P<0.01). Comparisons by χ
2 
test.
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Figure 2 | Blastocyst development following ePNT 
a, Autologous (Atlg) ePNT (i) and Heterologous (Het) ePNT (ii). b, Blastocyst 
formation and quality (series II). Zygotes (n=131 from 30 donors) were either 
unmanipulated (Ctr, n=30); or used for Atlg (n=21), or Het (n=80) ePNT. Het 
ePNT blastocyst formation was reduced compared with Ctr (P<0.05; χ
2 
test). 
Blastocyst quality is similar between the three groups (not significant; 
Fisher’s exact test). c, Images showing good quality control and ePNT
blastocysts. Arrowheads, ePNT blastocyst hatching through laser-induced 
opening in the zona pellucida. Scale bars, 20μm. d, Aneuploidy in cells 
sampled from blastocysts (grades A-F) detected by array-CGH blind to 
sample origin (n=blastocysts; not significant, Fisher’s exact test). e,
Aneuploidy in controls and ePNT blastocysts not significantly different from a 
reference population (Ref) of IVF blastocysts (χ
2 
test). (Source data available 
online for part b).
Figure 3 | Gene expression patterns in unmanipulated controls and 
ePNT blastocysts.
a, Principal Component Analysis (PCA) of single cell RNA-seq data showing 
global gene expression profiles in a reference population (n=30 samples; 8 
blastocysts), experimental controls (n=8 samples; 3 blastocysts) and ePNT 
blastocysts (n=56 samples; 11 blastocysts).  Each data point represents a 
single cell. ePNT blastocysts include heterologous (Het) autologous (Atlg)
16
and homologous (Homol) transfers (Extended Data Fig. 5b). The Het group is 
subdivided according to blastocyst grade. b, Graph shows an increased 
percentage of outliers in poor quality blastocysts (P values shown; Fisher’s 
exact test). c, PCA of single cell RNA-seq data comparing control samples 
with good quality ePNT blastocysts. PCA was performed blind to sample 
origin. The number of samples and blastocysts are shown. (Data deposited to 
Gene Expression Omnibus GSE76284).
Figure 4 | Carryover of karyoplast mtDNA in ePNT blastocysts. 
a, Reciprocal ePNT between zygotes from fresh and vitrified oocytes, 
enucleated in the presence or absence of sucrose resulting in four 
experimental groups: FreshCy ± sucrose; VitCy ± sucrose. b, MtDNA 
carryover in day 6 blastocysts arising from ePNT in the presence or absence 
of sucrose; horizontal lines represent means (P< 0.0005; two-sided Mann-
Whitney U test). c, MtDNA carryover in day 6 blastocysts (FreshCy and 
VitCy) following ePNT in the presence or absence of sucrose; horizontal lines 
represent medians (P vales shown, two-sided Mann-Whitney U test). Stacked 
graph showing the percentage of samples with specified levels of 
heteroplasmy. Groups with different letters are significantly different (* 
P<0.05; ** P<0.01; χ
2 
test). b,c Data points represent means of 2-3 technical 
replicates; n=number of samples, numbers of blastocysts as shown in c. d,
MtDNA carryover in PNT-hESC lines (n=5).  Data points represent 2-3
technical replicates. Median value (red) for each passage in which >1 sample 
17
was tested; n=number of samples tested for each passage. (Source data files 
available online for b-d). 
Online only information
Methods
Human oocytes and manipulations
The study was approved by the Newcastle and North Tyneside Research Ethics 
Committee and was licensed by the UK Human Fertilisation and Embryology 
Authority (HFEA).  Informed consent was obtained from all donors by research nurses 
who were not directly involved in the research, or in the clinical treatments of women 
participating in the study. Human oocytes (n=523) included in this study were donated 
either by women undergoing infertility treatment (n=44 oocytes from 6 donors, age 
range 25-36 years) as part of an “egg sharing” programme27, or by non-patient donors 
(n=479 oocytes from 57 donors, age range 21-36 years). Donors were compensated 
in accordance with current HFEA guidance on payments for donors28.  Non-patient 
donors received financial compensation of £500 per donation cycle.  Compensation 
under the “egg share” programme consisted of a subsidy (£1,500) from research funds 
towards the cost of treatment for self-funded patients27, or an additional fully funded 
treatment cycle for those who did not become pregnant following NHS-funded 
treatment. 
Oocytes were collected by ultrasound-guided follicle aspiration and the surrounding 
cumulus cells were removed using hyaluronidase (HYASE, Vitrolife).  MII oocytes 
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were identified by the presence of the 1st polar body and were fertilised by 
intracytoplasmic sperm injection (ICSI) using sperm donated specifically for this 
project.  
Oocyte Vitrification
MII oocytes were either vitrified or used immediately for PNT experiments.  The 
majority (n=107) of vitrified oocytes were vitrified at the MII stage.  We also 
conducted a series of experiments in which vitrification was performed following 
completion of MII (at the 2PB stage; ~5.5 hours post ICSI; n=34), to determine 
whether blastocyst development might be improved. Vitrification and warming were 
performed using the RapidVit and RapidWarm oocyte kits (Vitrolife, Sweden).  
Oocytes were stored in liquid nitrogen until required.
Pronuclear Transfer (PNT)
PNT was performed either at 16-20 hours after ICSI (Late PNT; LtPNT), or at ~8-10
hours after ICSI (early PNT; ePNT).  In the case of ePNT, two main series of 
experiments (Series I and Series II) were performed. A total of 51 zygotes from 10
donors were used for LtPNT (n=12 controls; n=39 LtPNT). For ePNT experiments 
we used 58 zygotes from 13 donors in Series I (n=19 controls; n=39 ePNT, and 131
zygotes from 30 donors in Series II (n=30 controls; n=101 ePNT).  Thirty-four 
zygotes from 13 donors were used for ePNT experiments involving oocytes vitrified at 
the 2PB stage.
19
Two types of PNT experiments were conducted: (1) Autologous (Atgl) PNT, which 
involved removal and replacement of PN in the same zygote was performed to 
distinguish between technical and biological effects.  (2) Heterologous (Het) PNT 
involved reciprocal transfer between pairs of zygotes, either from the same of different 
donors. Heterologous PNT between zygotes from different donors involved reciprocal 
transfer between zygotes originating from fresh and vitrified oocytes.  This gave rise to 
reconstituted zygotes consisting of cytoplasts from fresh oocytes and karyoplasts from 
vitrified oocytes, or vice versa. These combinations are termed FreshCy and VitCy 
respectively (see Extended Data Fig. 4a). In one set of ePNT experiments, which gave 
rise to a single ePNT blastocyst, the two donors were sisters and therefore have the 
same mitochondrial genotype. For the purpose of the gene expression experiments, 
these are referred to as homologous transfers.
The PNT procedure was performed in an isolator-based workstation (Vitrosafe Ltd) 
with temperature, CO2 and O2 control
29 containing an inverted microscope (TE2000-U, 
Nikon) fitted with micromanipulators (Integra Ti, Research Instruments) and a laser 
objective (Saturn Active, Research Instruments).  PNT procedures took ~15 min to 
complete and involved the following steps: (1) Zygotes in which 2PN were visible 
were placed in enucleation medium with cytoskeletal inhibitors. In all cases, 
nocodazole (10µg/ml) was used to depolymerise microtubules.  In LtPNT experiments 
we used either cytochalasin B (5µg/ml) or Latrunculin A (2.5 µM or 5 µM) to disable 
the actin cytoskeleton.  We subsequently used Latrunculin A (2.5 µM) for all ePNT 
experiments. For LtPNT and ePNT (series I) experiments, enucleation was performed 
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in G-1 Plus medium (Vitrolife, Sweden). We used Sydney IVF Embryo Biopsy 
Medium (Cook Medical), which does not contain Ca2+ and Mg2+ for ePNT (Series II) 
experiments.  Enucleation was performed in the presence or absence of sucrose 
(0.125µm). Addition of sucrose increased the osmolarity of the enucleation medium 
from 280 mosm/L to 449 mosm/L, which induced shrinkage of the cytoplasm, thereby 
facilitating enucleation.  (2) A laser objective (Saturn Active, Research Instruments) 
was used to create an opening in the zona pellucida for insertion of the 
enucleation/fusion pipette. The inner diameter pipette measurements were 25-35µm
for LtPNT, and 17µm for ePNT. (3) The PN, surrounded by a small amount of 
cytoplasm, were aspirated into the enucleation pipette, either as a single karyoplast, or 
as two separate karyoplasts (see Videos 1 and 2).  (4) Karyoplasts were briefly 
exposed to a suspension of HVJ-E; GenomONE-CF Ex (Cosmo Bio, Japan).  
Undiluted suspension was used for LtPNT and ePNT (Series I) and a 1:10 dilution was 
used for ePNT (Series II). (5) The pipette containing the karyoplasts was inserted 
through the laser-drilled opening in the zona pellucida and karyoplasts were gently 
expelled into the perivitelline space and allowed to fuse with the cytoplast.  (6) 
Reconstituted and control zygotes were cultured either in a sequential medium G-1 
Plus (day 1-3)/ G-2 Plus (day 3-6) (Vitrolife; LtPNT and ePNT (series I)), or in the 
single-step G-TL medium (Vitrolife; ePNT (series II)) from day 1-6. Time-lapse 
embryo imaging was performed for three sets of ePNT (Series II) experiments using 
the Primo Vision Time-lapse monitoring system (Vitrolife, Sweden).
Overview of experiments on PNT zygotes
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Survival of reconstituted zygotes was initially compared between LtPNT and ePNT 
(Series I) and was subsequently recorded for all ePNT zygotes.  In ePNT (Series II), 
the first mitotic division was monitored by time-lapse imaging in two experiments.  All 
zygotes submitted to PNT were included in the analysis of development to the 
blastocyst stage. Zygotes (controls and PNT) that developed to the blastocyst stage 
were graded and included in the analysis of blastocyst quality. Blastocyst formation 
and grade were assessed on day 6 for LtPNT, and on days 5 and 6 for ePNT, except in 
the case of two ePNT (Series II) experiments, which were assessed only on day 6.  
These experiments are not included in the day 5 analysis shown in Fig. 2b and in 
Extended Data Fig. 3d-f.
Blastocyst cell counts were performed primarily to gain insight into the causes of poor 
blastocyst quality in the LtPNT and ePNT (Series I). Data on blastocyst cell counts 
were obtained from LtPNT (n=6) and ePNT: Series I (n=8) and Series II (n=5).  
Further analyses, including aneuploidy, gene expression, mtDNA carryover, and hESC 
derivation were conducted on Series II blastocysts only.  Where possible, we 
performed multiple investigations on individual blastocysts. In accordance with our 
Local Research Ethics Committee approval and HFEA licence, these were performed 
on day 6. Unmanipulated control blastocysts and ePNT blastocysts were used for 
aneuploidy and gene expression, or aneuploidy and hESC derivation.  The blastocyst 
grades shown for each of these analyses refer to the grades on day 6.  The numbers of 
blastocysts used for each set of experiment were:  Aneuploidy screening (PNT: n=30 
from 20 donors; Control: n=11 from 10 donors), gene expression analysis (PNT: n=11 
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from 10 donors; Control: n=3 from 3 donors), mtDNA carryover (PNT: n=40 from 28 
donors), hESC derivation (PNT: n=15 from 13 donors; Control: n=6 from 4 donors).
Embryo grading
Embryos were graded using the UK National External Quality Assessment Service 
(NEQAS) grading schemes for embryos and blastocysts30. Blastocysts were assigned a 
three digit grade representing a score of: 1-6 for the extent of blastocoel expansion, 1-
5 for the inner cell mass appearance and 1-3 for the trophectoderm appearance31.  The 
grade was converted to a quality category using the table in Extended Data Fig. 2c.
Blastocyst Nuclear Counts
Day 6 blastocysts were fixed using 4% PFA at pH 7.4.  Nuclear staining was carried 
out using DAPI (Vectashield). Blastocysts were imaged using an inverted confocal 
microscope (Nikon AIR, Japan) with a 20X objective (Plan Apo, Nikon) and NIS-
elements image software. Z-steps were taken at ~1µm intervals and nuclear counts 
performed using ImageJ software.
Aneuploidy screening
Clumps of cells were harvested from ePNT blastocysts for whole genome amplification 
followed by microarray-CGH analysis according to a previously validated protocol 
using 24Sure Cytochip (Illumina, Cambridge, UK). Cells were obtained from the TE, 
ICM or both. Lysis and whole genome amplification was performed using the SurePlex 
kit (Illumina) according to the manufacturer's instructions. Samples from ePNT 
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blastocysts were labelled with Cy3 while a commercially available reference 46,XY 
DNA was labelled with Cy5 (Illumina)32. A laser scanner (InnoScan 710, Innopsys, 
Carbonne, France) was used to analyse the microarrays after washing and drying. The 
resulting images were analysed using BlueFuse Multi analysis software (Illumina). 
Gene expression analysis by single cell RNA-seq
Blastocyst disaggregation
Blastocyst disaggregation was performed using an Olympus IX73 microscope and a 
Saturn 5 laser (Research Instruments) as described previously14. Embryos were placed 
in drops of G-MOPS solution (Vitrolife, Sweden) on a petri dish overlaid with mineral 
oil for micromanipulation. The separated ICM and polar TE were washed in Ca2+ and 
Mg2+ -free PBS (Invitrogen) and incubated in 0.05% trypsin/EDTA (Invitrogen) for 5-
10 minutes. Trypsin was quenched using Global Media supplemented with 5 mg/mL 
LifeGlobal Protein Supplement. Single cells were isolated using a 30µm inner diameter 
blastomere biopsy pipette (Research Instruments).
cDNA synthesis and amplification
cDNA was synthesised using SMARTer Ultra Low Input RNA for Illumina 
Sequencing-HV kit (Clontech Laboratories, Inc.) according to the manufacturer’s 
guidelines and as previously published14. cDNA was sheared using Covaris S2 with the 
modified settings 10% Duty, Intensity 5, Burst Cycle 200 for 2 min. Libraries were 
prepared using Low Input Library Prep Kit (Clontech Laboratories, Inc.) according to 
manufacturer’s instructions.  Library quality was assessed with an Agilent 2100 
BioAnalyser and concentration measured with a Qubit 2.0 Fluorometer (Life 
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Technologies UK Ltd.). Libraries were submitted for 50-bp paired-end sequencing 
using standard Illumina adapters on Illumina HiSeq 2000. Samples with primer 
contamination and amplification bias, identified by an unequal proportion of ATGC 
nucleotide percentages, were excluded from subsequent analysis.
RNA-seq data analysis
The quality of the RNA-seq data was evaluated using the FastQC tool. Reads were 
aligned to the human genome sequence hg19 using Tophat233, and samples with low 
percentage mapping (<50%) were excluded from subsequent analysis. The number of 
reads mapping uniquely to each gene was counted using the program htseq-count34. 
The individual count files for each sample were normalised using both the RPKM 
function in the edgeR package35 and a variance-stabilizing transformation from the
DESeq2 package36.
A principal component analysis (PCA) of the top 12,000 most variably expressed 
genes was performed blind to sample origin on all ePNT and control samples to 
investigate differences in global gene expression. The PCA was generated using the R 
package prcomp, using both the scaling and centering options. A subsequent PCA 
excluded samples below grade C, which were generally aneuploid for multiple 
chromosomes. An R script was used to perform unsupervised hierarchical clustering
and to generate a heatmap using the pheatmap R package. An alternative approach for 
data dimensionality reduction was performed using the t-SNE algorithm. The top 5 
principal components of the VST-normalised count data were used as input for the R 
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implementation of t-SNE. DESeq2 was applied to the read counts for the ePNT and 
control data to identify differential expressed genes in the primitive endoderm, 
trophectoderm and epiblast samples. Raw data and an RPKM table have been 
deposited into Gene Expression Omnibus (GSE76284).
MtDNA carryover analysis
MtDNA extraction and mtDNA sequencing
The control region of the mitochondrial genome from oocyte donors was sequenced 
using ovarian follicular cells harvested at the time of oocyte retrieval, or cumulus cells 
removed from the oocyte in preparation for ICSI. DNA extraction from follicular cells 
was performed using the QIAamp® DNA Mini kit according to the manufacturer’s 
instructions (Qiagen). Cumulus cells were lysed for 2 hours in a lysis buffer (50mM 
Tris-HCl, pH 8.5, 1mM EDTA, 0.5% Tween-20 and 200μg/ml proteinase K) at 55°C.  
The enzyme was then inactivated by incubation at 95°C for 10 minutes. The control 
region of the mitochondrial genome was amplified as described previously37 with the 
following modification: secondary PCR reactions were performed with 4 sets of 
overlapping M13-tailed primers (primer nucleotide positions: D1F: 15758-15777 and 
D1R: 019-001, D2F: 16223-16244 and D2R: 129-110, D3F: 16548-16569 and D3R: 
389-370, D4F: 323-343 and D4R: 771-752) with an annealing temperature of 58°C.  
PCR products were purified using TSAP (Promega) then sequenced on an ABI3130 
Genetic Analyser (Applied Biosystems) with BigDye Terminator cycle sequencing 
chemistries (v3.1, Applied Biosystems).  Sequences were directly compared to the 
revised Cambridge Reference Sequence for human mtDNA38 (GenBank Accession 
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number: AC_000021.2) using SeqScape software (v2.1.1, Applied Biosystems).
Generation of heteroplasmic control DNA
The mtDNA control region containing either the wild-type or polymorphic nucleotide 
of interest was amplified using PCR primers (primer nucleotide positions: forward 
primer 16016-16036, reverse primer 571-552) with an annealing temperature of 58°C.  
PCR products amplified from ovarian follicular cells were purified using the Agencourt 
AMPure XP purification system (Beckman Coulter) according to the manufacturer’s 
instructions.  PCR products amplified from cumulus cells were gel purified (QIAquick 
Gel Extraction kit, Qiagen) and cloned using the pGEM®-T Easy Vector System 
(Promega) according to the manufacturer’s instructions.  Plasmid DNA was isolated 
using the QIAprep Spin Miniprep kit (Qiagen).  Quantitative real-time PCR was 
performed using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen) and 
PCR primers (forward primer L16016-16036, reverse primer, H16186-16167) to 
accurately determine the DNA concentration.  Equimolar concentrations of DNA
containing the wild-type or polymorphic nucleotide of interest were then combined in 
varying ratios to generate a range of heteroplasmic controls.
Pyrosequencing
Quantitative pyrosequencing was used to measure mtDNA carryover in samples from 
ePNT blastocysts and PNT-hESC lines. Locus-specific PCR and a pyrosequencing 
primer were designed for each polymorphic nucleotide of interest the mtDNA using 
PyroMark Assay Design Software v2.0 (Qiagen). Clumps of cells from ePNT 
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blastocysts and from PNT-hESC lines were lysed for 2 hours in a lysis buffer (50mM 
Tris-HCl, pH 8.5, 1mM EDTA, 0.5% Tween-20 and 200μg/ml proteinase K) at 55°C.  
The enzyme was then inactivated by incubation at 95°C for 10 minutes.  MtDNA 
amplification was performed prior to pyrosequencing analysis and pyrosequencing 
performed on the PyroMark Q24 and PyroMark Q96 instruments according to the 
manufacturer’s instructions.  Quantification of the heteroplasmy level was achieved 
using the instrument software to directly compare the relevant peak heights of both the 
wild-type and polymorphic nucleotides at the relevant position14.  A standard curve 
was generated by plotting expected heteroplasmy level against actual heteroplasmy 
level for the control samples.  The standard curve was used to determine the level of 
heteroplasmy in the blastocyst and PNT-hESC samples.
Mitochondrial haplogroups
Haplogroups were determined by next generation sequencing analysis of whole 
mtDNA, amplified in two overlapping 9kb fragments using primers L550-569 and 
H9839-9819 (set 1) and L9592-9611 and H645-626 (set 2), on an Ion Torrent 
Personal Genome Machine (Life Technologies) 39.  Protocol modifications included use 
of a OneTouch 2 system and HiQ OT2 and sequencing kits. Samples were processed 
on Ion 316 chips and analysed with Torrent Suite Variant Caller plugin (version 4.6). 
Embryonic stem cell derivation
For inner cell mass (ICM) isolation day 6 blastocysts were dissected in the embryo 
culture dish. The blastocysts were held in position by a holding pipette (Vitrolife, 
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Sweden) with the ICM at 3 o’clock. The ICM was held in position with a biopsy 
pipette (Origio, Cat. No. MPB-FP-30) and isolated from the majority of the 
trophectoderm cells by laser pulses (Saturn 5 Active, Research Instruments). The 
isolated ICMs were plated on inactivated feeders MEF (CF1s), in medium containing 
KnockOut Serum Replacement (Invitrogen. Cat No. 10828), KnockOut DMEM 
(Invitrogen. Cat No. 10829), NEAA (Invitrogen. Cat No. 11140), bFGF2 (Invitrogen. 
Cat No. 13256), Glutamax (Invitrogen. Cat No. 35050) and 2-Mercaptoethanol 
(Invitrogen. Cat No. 21985). Outgrowths were mechanically dissected from the 
surrounding cells and plated on fresh feeder cells, all subsequent passaging was 
performed mechanically. Embryonic stem cells were adapted to feeder-free culture 
conditions and maintained in mTeSR1 (STEMCELL Technologies) on growth factor 
reduced Matrigel (BD Biosciences).
Quantitative RT-PCR (qRT-PCR)
RNA was isolated using TRI Reagent (Sigma) and DNaseI treated (Ambion). 
cDNA was synthesized using a Maxima First Strand cDNA Synthesis Kit 
(Fermentas). qRT-PCR was performed using Quantace Sensimix on an 
Applied Biosystems 7500 machine (Life Technologies Corporation, 
California, USA). Primer pairs used were previously published
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 and are as 
follows: NANOG forward GCAACCTGAAGACGTGTGAA, reverse 
CTCGCTGATTAGGCTCCAAC; POU5F1 forward 
TATGGGAGCCCTCACTTCAC, reverse CAAAAACCCTGGCACAAACT; 
SOX2 forward TTGTTCGATCCCAACTTTCC, reverse 
ACATGGATTCTCGGCAGACT.
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Immunohistochemistry and imaging
Samples were fixed in 4% paraformaldehyde at 4°C overnight, permeabilized 
with 0.5% Tween in 1X PBS for 20 minutes and blocked with 10% FBS 
diluted in 0.1% Tween in 1X PBS for 1 hour. Primary antibodies were diluted 
in blocking solution as indicated: AFP (Dako, A0008, 1:500), Desmin 
(Neomarkers/Thermo, RB-9014-P, 1:50), Nanog (R&D, AF1977, 1:500), Oct4 
(Santa Cruz, SC-5279, 1:500), SMA (Sigma, A5228, 1:250), Sox1 (R&D, 
AF3369, 1:500), Sox2 (Cell Signalling, 23064, 1:500), Sox17 (R&D, AF1924, 
1:500), SSEA4 (DSHB, MC-813-70, 1:100), Tuj1 (Sigma, T2200, 1:500). 
Samples were incubated at 4°C rotating overnight.  Alexa Fluor secondary 
antibodies (Invitrogen, anti-mouse A21202, A21203; anti-rabbit A21206, 
A21207; anti-goat A11055, A11058) were diluted 1:300 in blocking solution 
and samples incubated for 1 hour at room temperature, then washed and 
covered with 0.1% Tween in 1X PBS containing DAPI Vectashield mounting 
medium (Vector Labs).  Images were taken on an Olympus 1X73 microscope 
with Cell^F software (Olympus Corporation, Tokyo, Japan).
Statistical Analysis
Data were analysed using one-way ANOVA with Tukey’s HSD test, Mann-
Whitney U test, χ
2
 test and Fisher’s exact test, as indicated in the figure 
legends. RNA-seq data were analysed by PCA using either RPKM- or VST-
normalized counts.  
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Extended Data Figure 1 | Late PNT and PN centralisation following early 
PNT.
a, Schematic showing timing of late PNT (LtPNT) and early PNT (ePNT). b, 
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Images showing the stages of the LtPNT process.(i) late PN zygote (ii) 
enucleation (iii) fusion. Scale bar, 20µm. Note large pronuclei and pipette 
size compared with Fig. 1b and Videos 1 and 2. c, Images show 
unmanipulated and ePNT zygotes at 16-18 hr after fertilization. Scale bars, 
20μm. d, PN centralization and division to the 2-cell stage assessed by live 
cell imaging in control and ePNT zygotes (not significant). Comparisons by χ
2 
test.
Extended Data Figure 2 | Blastocyst morphology and effect of PNT on 
blastocyst development and quality. 
a, Schematic showing cell lineages in a mammalian blastocyst: 
Trophectoderm (TE); Primitive endoderm (PE) and Epiblast (Epi). b, 
Morphological criteria and scoring system used for grading human 
blastocysts
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. Top panel shows degree of expansion ranging from an early, 
unexpanded blastocyst (score 1) to fully expanded (score 6). Middle panel 
shows a range of inner cell mass (ICM) morphologies ranging from absent 
(score 1) to large but tightly packed (score 5). Bottom panel shown a range of 
trophectoderm (TE) morphologies ranging from scant and discontinuous 
(score 1) to a fully formed layer of tightly packed cells (score 3). Box colours 
correspond to the grades shown in c. c, Table used to assign blastocyst 
grades, according to levels of expansion, and morphology of the ICM and TE.
Grade F (not shown) was assigned to embryos that developed to the 
blastocyst stage but subsequently showed signs of degeneration. d, Graph 
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showing the relationship between blastocyst grade and implantation. Data 
obtained from clinical IVF cycles (n=531) in which unmanipulated single 
blastocysts were replaced on day 5. Implantation is defined by the detection 
of a fetal heartbeat at 6 weeks after IVF treatment. There was no case in 
which a grade D or F blastocyst was replaced. P values are shown (χ
2
 test).  
e, LtPNT experimental conditions, blastocyst formation (P<0.01; χ
2 
test) and 
quality. A total of 51 zygotes from 10 donors were allocated either to an 
unmanipulated control group (Ctr, n=12) or to LtPNT involving transfer 
between pairs of zygotes from the same donor (n=29) or replacement back 
into the same zygote (Autologous PNT (Atlg) n=10). f, ePNT (series I) 
experimental conditions, blastocyst formation and quality. This series of 
experiments involved a total of 58 zygotes from 13 donors. Zygotes were 
allocated to a control group (Ctr, n=19), or to ePNT involving either 
autologous (Atlg, n=18) or heterologous (Het, n=21) transfers. Differences 
are not significant (χ
2 
test and Fisher’s exact test). g, Image of an ePNT 
blastocyst fixed on day 6 and stained with DAPI. Scale bar, 50µm. h, Cell 
number assessed by nuclear counts showing comparable numbers in control 
and ePNT (Series II) blastocysts and significantly reduced numbers in LtPNT 
and ePNT (Series I) blastocysts (P=0.001; one-way ANOVA with Tukey’s 
HSD test). Mean ± s.d. calculated from individual blastocysts, numbers 
indicated on the x-axis.
Extended Data Figure 3 | Survival and blastocyst development following 
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ePNT between zygotes obtained from freshly harvested and vitrified 
oocytes.
a, Experimental scheme for heterologous ePNT in Series II.  Because of 
unpredictability in the response to ovarian stimulation, heterologous transfers 
involved reciprocal ePNT between zygotes generated from freshly harvested 
and vitrified oocytes. This resulted in reconstituted zygotes whose cytoplasts 
originated from a fresh oocyte (FreshCy), or from a vitrified oocyte (VitCy). 
Oocytes for these experiments were vitrified predominantly at the MII stage 
(blue box; n=80 zygotes; 25 donors).  We also conducted a series of 
experiments to determine whether vitrification at the 2PB stage (green box; 
n=34 zygotes; 13 donors) would promote improved blastocyst formation. b, 
Survival of reconstituted zygotes as a proportion of those submitted to 
autologous (Atlg) and heterologous (Het) ePNT according to the stage of 
vitrification (MII or 2PB) and according to whether the cytoplast was derived 
from a fresh (FreshCy) or a vitrified (VitCy) oocyte.  Loss was generally due 
to karyoplast lysis, excessive leakage of cytoplasm, or degeneration of 
reconstituted zygotes during subsequent incubation. Differences are not 
significant (χ
2
 test). c, Sucrose was initially included in the manipulation 
medium to facilitate enucleation and fusion, however it was later removed 
because the data indicated that the osmotic effect resulted in increased 
mtDNA carryover (see Fig. 4b). Omission of sucrose from the enucleation 
medium had a small, but not significant, effect on survival of zygotes whose 
cytoplasts originated from vitrified MII oocytes (χ
2
 test). d, Blastocyst 
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formation as a percentage of zygotes submitted to the ePNT procedure 
recorded on days 5 and 6 following fertilisation.  e, Blastocyst formation 
recorded on days 5 and 6 as a percentage of zygotes that survived the ePNT 
procedure. The numbers in each group and P values are shown, χ
2
 test.  f, 
Blastocyst quality grades  (see Extended Data Fig. 2 c,d) on days 5 and 6 
(not significant; Fisher’s exact test). (Source data files available online).
Extended Data Figure 4 | Array-CGH results for PNT blastocysts.
Summary of array-CGH results obtained from inner cell mass and 
trophectoderm samples from control (n=11) and ePNT (n=30) blastocysts. 
Blastocysts are ordered by grade within experimental groups. The karyoplast 
donor age is also shown.
Extended Data Figure 5 | Experimental approach and bioinformatics 
analysis of single cell RNA-seq data from ePNT and control blastocysts.
a, Flow diagram showing the steps involved in RNA-seq of single cells 
microdissected from human blastocysts. b, Summary table of control and 
ePNT blastocysts submitted for RNA-seq analysis. For the purpose of gene 
expression analysis, we distinguish between ePNT blastocysts derived from 
fusion of cytoplasts and karyoplasts with the same and different mitochondrial 
genomes. Those with the same mitochondrial genomes included blastocysts 
from autologous ePNT and from zygote pairs donated by two sisters, which 
we refer to as homologous ePNT. Blastocysts arising from heterologous 
37
ePNT represent new combinations of nuclear and mitochondrial genome and 
are sub-grouped according to the cytoplast origin (see Extended Data Fig. 4). 
c, Flow diagram outlining the bioinformatics analysis of RNA-seq data. Data 
were normalized either as reads per kilobase per million mapped reads 
(RPKM)
41
 or using DESeq2
36
 Normalized data were used to generate 
principal component analysis (PCA) plots, t-SNE plots and heatmaps. RNA-
seq data has been deposited to Gene Expression Omnibus (GSE76284).
Extended Data Figure 6 | Analysis of differential gene expression in 
good quality ePNT and control blastocysts.
a, PCA matrix using the first ten principal components of DESeq2 VST 
normalized data for the top 12,000 most variable genes. Global gene 
expression is indistinguishable between unmanipulated control and ePNT 
samples, PC1 versus PC2 highlighted in blue box. b, PCA matrix as shown 
in a., distinguished by lineage, clearly seen in PC2 versus PC3 (pink box). c, 
t-SNE analysis following DESeq2 VST normalization of 6,000 of the most 
variably expressed genes, where samples were distinguished by lineage. 
Sample numbers and blastocyst grades are shown. Autologous and 
homologous ePNT samples are derived from blastocysts in which the 
karyoplast and cytoplast had the same mitochondrial genome. Heterologous 
ePNT samples were derived from pairs of zygotes with different mitochondrial 
genomes (Extended Data Fig. 5). Samples from experimental controls and 
reference population were combined for the purpose of the analyses shown 
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in a and b. 
Extended Data Figure 7 | Expression of lineage specific genes and 
mitochondrial OXPHOS genes in control and ePNT embryos.
a, Heatmap showing log2 transformed RPKM values of selected differentially 
expressed genes in trophectoderm (n=10), epiblast (n=10) and primitive 
endoderm (n=10) lineages.  b, Heatmap showing expression of mitochondrial 
OXPHOS genes following unsupervised hierarchical clustering. Expression of 
OXPHOS genes encoded by mtDNA is variable both within and between 
blastocysts.  Control and ePNT samples cluster together, irrespective of 
whether the cytoplast and karyoplast had the same (blue font) or different 
(purple font) mtDNA. Sample numbers and blastocyst grades are shown.  The 
reference population includes a previously published series
14
. Autologous 
and homologous ePNT samples are derived from blastocysts in which the 
karyoplast and cytoplast had the same mitochondrial genome.  Heterologous 
ePNT samples were derived from pairs of zygotes with different mitochondrial 
genomes (Extended Data Fig. 5b). Expression levels are indicated on a high-
to-low scale (purple-white-green). (Source data files available on line for 
parts a and b) 
Extended Data Figure 8 | Measurement of heteroplasmy due to mtDNA 
carryover during ePNT. 
a, Mitochondrial genotypes were determined by identifying polymorphic 
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variants in the hypervariable mtDNA control regions of each donor. Sequence 
electropherograms of mtDNA non-coding control region with a sequence 
variant used for pyrosequencing (highlighted) (m.73A>G). b, Sequence 
pyrograms for the mtDNA variant (m.73A>G) in control samples. The 
expected level of variant is given along with the level determined by 
pyrosequencing (in brackets). c, Examples of the standard curve generated 
to increase accuracy in detecting low levels (0-25%) of heteroplasmy by 
pyrosequencing, which has previously been reported to accurately detect 
heteroplasmy at a level of 1%
42
. Each data point represents the mean of 3-4 
technical replicates. d, MtDNA carryover was measured by pyrosequencing 
using clumps of cells (n=92) from day 6 blastocysts (n=40; names shown on y 
axis). The cells were predominantly obtained from the TE layer (purple, 
n=67).  ICM cells (red, n=5) and cells of mixed TE/ICM origin (green, n=20) 
were also analysed. Each data point represents the mean of 2-3 technical 
replicates.  e, MtDNA carryover from individual blastocysts calculated from 
data shown in d.  Each data point represents either the mean value where >1 
sample was tested (n=28 ePNT blastocysts), or a single value where only 
one sample was tested (n=12 ePNT blastocysts). Horizontal lines show 
median values for each experimental group.  Blastocysts arising from ePNT 
performed in the absence of sucrose and fused with a fresh cytoplast 
(FreshCy) had significantly reduced mtDNA carryover compared with 
blastocysts where ePNT was performed in the presence of sucrose (P values 
and blastocyst numbers are shown; two-sided Mann-Whitney U test). f, 
40
Graph showing the proportions of blastocysts (n=40) with mtDNA carryover 
measurements falling within the specified levels (not significant: χ
2
 test). 
(Source data files provided for parts c-f).
Extended Data Figure 9 | Derivation and characterisation of human 
embryonic stem cells from control and ePNT blastocysts.
a, Examples of outgrowths formed following explantation of the ICM from 
ePNT (n=15) and control (n=6) blastocysts used for hESC derivations.  The 
dashed white circle indicates the region picked for initial passage of the ICM 
outgrowth.  Bottom panel shows examples of hESC colonies. b, Example of a 
normal karyogram from an PNT-hESC line (45PNT); 4/4 lines tested showed 
a normal karyotype.  The remaining hESC line did not grow beyond passage 
2 and was derived from a uniformly aneuploid blastocyst (55PNT; Extended 
Data Fig. 4). c, Immunostaining of representative PNT-hESCs (grown in 
mTeSR1) for NANOG, SSEA4 (green), SOX2 and OCT4 (red) with DAPI 
(blue) merge. Graph shows qRT-PCR analysis of control and PNT-hESC 
lines for pluripotency transcripts NANOG, POU5F1 and SOX2. Horizontal line 
shows the median value, which is similar between hESCs from 
unmanipulated control blastocysts (Ctr; n=2 hESC lines) and ePNT-
hESCs.(n=4 ePNT-hESC lines). d, Immunostaining of representative PNT-
hESCs after 20 days in basal MEF media, confirming differentiation into all 
three germ layers: endoderm (alpha-fetoprotein, AFP; SOX17), mesoderm 
(alpha-smooth muscle actin, SMA; desmin, DES) and ectoderm (beta-III 
41
tubulin, TUJ1; SOX1) in green or red, with DAPI (blue) merge. Scale bars, 50
μm.  e, Table showing the mtDNA variants and primers used to measure 
mtDNA carryover in PNT-hESC lines. f, Summary table showing details of 
blastocysts and the corresponding hESCs. Aneuploidy in PNT-hESC lines 
was analysed by metaphase spreads, except for 31PNT-hESC, which was 
determined by array-CGH.
Extended Data Figure 10 | Heteroplasmy in subclones of the hESC line 
derived from 36PNT.
a, The 36PNT hESCs line was frozen at passage 3 (after derivation), thawed 
and subcloned to monitor heteroplasmy arising from the karyoplast donor 
mtDNA. Six colonies (15-20) were randomly selected at the first post-thaw 
passage (P3) and clumps of cells were plated on 3 tissue culture wells; 5/6 
colonies gave rise to 3 subclones which were grown to P11.  Sub-clones are 
distinguished by colour in the graphs. Each data point represents the mean of 
two technical replicates for a single cell sample. (Source data file available 
online).
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